Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Status:
Completed
Trial end date:
2021-04-16
Target enrollment:
Participant gender:
Summary
This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine
sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in
the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborators:
National Cancer Institute (NCI) National Comprehensive Cancer Network